tbuckley/cabot-search huggingface dataset:
Are corticosteroid injections more beneficial than anaesthetic injections alone in the management of rotator cuff-related shoulder pain? A systematic review
Authors: Tim Cook, Catherine Minns Lowe, Mark Maybury, Jeremy S Lewis
Journal: British Journal of Sports Medicine (2018)

Objective To compare the effectiveness of corticosteroid injections to local anaesthetic injections in the management of rotator cuff-related shoulder pain (RCRSP). Design Systematic review with best evidence synthesis. Data sources The Cochrane, PubMed, CINAHL Plus, PEDro and EMBASE electronic databases were searched (inception until 8 June 2017). Reference lists of included articles were also hand searched. Eligibility criteria Two reviewers independently evaluated eligibility. Randomised controlled trials (RCTs) were included if they compared subacromial injections of corticosteroid with anaesthetic injections. Two reviewers independently extracted data regarding short-term, midterm and long-term outcomes for pain, self-reported function, range of motion and patient-perceived improvement. Results Thirteen RCTs (n=1013) were included. Four trials (n=475) were judged as being at low risk of bias. Three studies of low risk of bias favoured the use of corticosteroid over anaesthetic-only injections in the short term (up to 8 weeks). There was strong evidence of no significant difference between injection types in midterm outcomes (12–26 weeks). There was limited evidence of no significant difference between injection types in long-term outcomes. Conclusion Corticosteroid injections may have a short-term benefit (up to 8 weeks) over local anaesthetic injections alone in the management of RCRSP. Beyond 8 weeks, there was no evidence to suggest a benefit of corticosteroid over local anaesthetic injections. Trial registration number PROSPERO CRD42016033161.
Immunomodulatory effects of tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) patients.
Authors: Marianna Nuti, Ilaria Zizzari, Chiara Napoletano, Andrea Botticelli, Fabio Calabro, Alain Gelibter, Aurelia Rughetti, Alessio Ugolini, Ilary Ruscito, Federica Mazzuca, Hassan Rahimi, Concetta Elisa Onesti, Enrico Cortesi, Paolo Marchetti
Journal: Journal of Clinical Oncology (2017)

e14506 Background: RCC is considered a highly immunogenic tumor responding to anti-angiogenetic TKI and immunotherapy. A better understanding of the functions of immune cells in RCC, the immune-modulatory effects of TKIs treatment as well as defining patients most likely to benefit to the different therapies will be crucial to optimize combined or sequential immunotherapeutic approaches in RCC patients. Methods: Monocyte derived Dendritic Cells (DCs) from 10 healthy donors were differentiated in presence of Pazopanib and Sunitinib used at plasmatic equivalent concentration (Sigma-Aldricht). At the end of the culture, DCs were characterized for marker expression, endocytosis, signal transduction and microvesicle release. Similarly, DCs derived from RCC patients were analyzed together with circulating T cells before and during TKI treatments. Results: Pazopanib and Sunitinib differently affect DC differentiation. Pazopanib, but not Sunitinib, strongly improves DC performance as antigen-presenting cells, promoting the upregulation of the maturation markers HLA-DR (+1,5 fold increase compared to Sunitinib-treated DCs), CD40 (+3 fold increase) and CCR7 (+2 fold increase) a decrease in phagocytosis and the inhibition of pERK1/2 signaling. 99% of Sunitinib-DCs expressed PD-L1 vs 80% Pazopanib-DCs , with a higher expression of the receptor as indicated by mean fluoresce intensity (MFI fold increase of +2,1). Similar results were obtained analyzing shedded microvesicles. Results were confirmed in DCs differentiated from RCC patients during Pazopanib treatment (before and at 30 and 60 days) and suggest a reverse of the tumor induced immunosuppression. Moreover, only Pazopanib treatment appears to induce in these patients a defined circulating CD4 + T cell population highly expressing CD137 molecule (%CD4 + CD137 + : T 0 :0,3; T 30 : 4,7; T 60 :29,4). Conclusions: TKIs can affect immunity in RCC patients. In particular, Pazopanib appears to function as a potent activator of DCs in vitro and in vivo associated with the neo-activation of a CD137+ T cell population. These results can guide for designing novel protocols to combine TKIs with immunoregulatory receptors targeting in RCC.
Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease
Authors: Meng-Ting Wang, Jun-Ting Liou, Chen Wei Lin, Chen-Liang Tsai, Yun-Han Wang, Yu-Juei Hsu, Jyun-Heng Lai
Journal: JAMA Internal Medicine (2018)

The associations between cardiovascular disease (CVD) and inhaled long-acting β2-agonists (LABAs) or long-acting antimuscarinic antagonists (LAMAs) in chronic obstructive pulmonary disease (COPD) are greatly debated. Pivotal and relevant randomized clinical trials included prior LABA or LAMA users and excluded patients with baseline CVD; therefore, cardiovascular events arising from first-time LABA or LAMA use, if any, could not be observed. There is an urgent need to examine whether new use of and duration since initiating LABAs and LAMAs could act as important determinants of cardiovascular events.To investigate risk of CVD associated with LABAs and LAMAs, focusing on the initiation and duration of LABA and LAMA therapies.This nested case-control study included 284 220 LABA-LAMA-naïve patients with COPD at least 40 years old (mean age, 71.4 years; 68.9% men), retrieved from the Taiwan National Health Insurance Research Database for health care claims from 2007 to 2011.LABA or LAMA use was measured in the year preceding the event or index date, stratified by duration since initiation of LABA or LAMA treatment, new and prevalent users, concomitant COPD medications, and individual agents.Cases with inpatient or emergency care visits for coronary artery disease, heart failure, ischemic stroke, or arrhythmia were identified and individually matched to 4 randomly selected controls. Conditional logistic regressions were performed to estimate odds ratios of CVD from LABA and LAMA treatment.During a mean follow-up of 2.0 years, 37 719 patients with CVD (mean age, 75.6 years; 71.6% men) and 146 139 matched controls (mean age, 75.2 years; 70.1% men) were identified. New LABA and LAMA use in COPD was associated with a 1.50-fold (95% CI, 1.35-1.67; P < .001) and a 1.52-fold (95% CI, 1.28-1.80; P < .001) increased cardiovascular risk within 30 days of initiation, respectively, whereas the risk was absent, or even reduced with prevalent use. Individual LABA agents, LAMA dosage forms, and concomitant COPD regimens did not differ in the CVD risks. The risk persisted in an alternative case-crossover study and remained across subgroups without CVD history or prior exacerbations.New initiation of LABAs or LAMAs in patients with COPD is associated with an approximate 1.5-fold increased severe cardiovascular risk, irrespective of prior CVD status and history of exacerbations.
Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) after Multiple Myeloma: Assessment of Risk Factors
Authors: Gudbjorg Jonsdottir, Magnus Bjorkholm, Ingemar Turesson, Malin Hultcrantz, Anna Porwit, Yogesh Jethava, Ola Landgren, Sigurdur Y. Kristinsson
Journal: Blood (2017)
CMV Reactivation Post CD34+ Selected Allo-HCT Has Adverse Outcomes on Blood Counts Recovery
Authors: Roni Tamari, Christina Cho, Patrick Hilden, Taylor Borrill, Molly Maloy, H.R. Castro-Malaspina, Esperanza B. Papadopoulos, Ann A. Jakubowski, Genovefa Papanicolaou, Sergio A. Giralt, Miguel-Angel Perales
Journal: Blood (2017)
Abstract 19028: The Novel H2S Pro-Drug, SG-1002, Preserves Coronary Artery Vascular Reactivity in the Setting of Critical Limb Ischemia in Swine
Authors: Erminia Donnarumma, Amanda M Rushing, Sarah F Boisvert, Amy L Scarborough, David J Polhemus, Rishi K Trivedi, David J Lefer, Traci T Goodchild
Journal: Circulation (2016)

Introduction: Peripheral artery disease (PAD) including critical limb ischemia (CLI) leads to increased risk of myocardial infarction even in the absence of coronary artery disease (CAD). It has be...
Acute Promyelocytic Leukemia (APL) Induction Therapy and Incidence of Renal Insufficiency
Authors: Prachi Kharkhanis, Sheldon Bolds, Stephanie Debragga, Catherine R. Caprara, Kathryn Sarah Simon, Martha L. Arellano, Anand Jillella, Vamsi Kota
Journal: Blood (2017)
Cigarette Smoking and Cardiovascular Diseases
Journal: Circulation (1960)

1956, the American Heart Association issued a statement on smoking and cardiovascular diseases.Among other things, this statement indicated that the available evidence at that time was not sufficient to justify conclusions concerning a cause and effect relationship between cigarette smoking and increased death rates from coronary heart disease (Appendix 1).Sinee then, sufficient additional knowledge has been accumnlated to warrant a new report on cigarette smoking and its possible relationship to cardiovascular diseases.(See footnote and Appendices 2, 3, 4 and 5.)Up to the present, a number of medical studies (Appendix 5) have been made, nearly all demonstrating a statistical association be- tween heavy cigarette smoking and mortality (death) or morbidity (illness) froin coronary heart disease.In these studies, death rates from coronary heart disease (heart attacks) in middle-aged men were found to be from 50 to 150 per cent higher among heavy cigarette smokers than ainong those who do not smoke.This statistical association does not prove that heavy cigarette smoking causes coronary heart Smoking and health: Joint report of the study group on smoking and health.Science 125: 1129, 1957.disease, but the data strongly suggest that heavy cigarette smoking may contribute to or accelerate the development of coronary heart disease or its complications.Because coronary heart disease is the leading cause of death and a major cause of disability in the American population, the American Heart Association believes that these studies concerning cigarette smoking and coronary heart disease should be called to the attention of the medical profession, allied health professions, health educators, and the general public.The association recognizes the need for more knowledge and will continue to encourage systematic biological and medical research in order to determine whether a causal relationship exists between cigarette smoking and coronary heart disease and also to determine the effects of smoking in relation to strokes and other important aspects of cardiovascular diseases.
AB0145 The treatment of osteoarthrosis with dolgit cream in kazakhstan
Authors: BS Shakimova, VV Zhdanov, AA Zhankin
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> <h3>Methods</h3> The two weeks open trial of Dolgit (5% ibuprofen) cream was carried out in 49 patients (pts) with osteoarthrosis (OA) (10 men and 39 women, age range 43–71 years) with disease history about 6,4 years. The 30 pts had gonarthrosis, 6 pts had OA of shoulder joint and 13 pts had lesion of interphalangeal joints. Patients were given an application of 5% ibuprofen cream at the affected joints 3 times a day (600 mg of ibuprofen per day) during 2 weeks. <h3>Results</h3> Results obtained after 1st cutaneous application showed that reducing of joint pain was marked in 40 min in 10 pts (77%) with OA of interphalangeal joints and in an hour in half of pts with gonarthrosis and OA of shoulder joint. At 7<sup>th </sup>day joint pain score reduced in all pts from 1,9 to 1,3 (p &lt; 0,05), joint score – from 1,7 to 0,7 (p = 0,05), pain in movement had also reduced but not significantly (p &gt; 0,05). At the end of trial joint pain score decreased to 0,5 (p &lt; 0,05) in pts with OA of interphalangeal joints and OA of shoulder joint, and in pts with gonarthrosis it reached 1 (p &gt; 0,05). Joint score had the similar trend. <h3>Conclusion</h3> The final patient's treatment efficacy assessment was ?good? in 35 pts (71%) and satisfactory in others. Tolerability of Dolgit cream was good, but in one case were signs of light skin irritation that disappeared without interruption of treatment. Thus we consider the cutaneous application of Dolgit cream to be real alternative to systemic usage of NSAIDs in treatment of OA because of its good efficacy and tolerability.
(Pro)renin Receptor Inhibition Reprograms Hepatic Lipid Metabolism and Protects Mice From Diet-Induced Obesity and Hepatosteatosis
Authors: Liwei Ren, Yuan Sun, Hong Lu, Dien Ye, Lijuan Han, Na Wang, Alan Daugherty, Furong Li, Miaomiao Wang, Fengting Su, Wenjun Tao, Jie Sun, Noam Zelcer, Adam E. Mullick, A.H. Jan Danser, Yizhou Jiang, Yongcheng He, Xiongzhong Ruan, Xifeng Lu
Journal: Circulation Research (2018)

Rationale: An elevated level of plasma LDL (low-density lipoprotein) is an established risk factor for cardiovascular disease. Recently, we reported that the (pro)renin receptor ([P]RR) regulates LDL metabolism in vitro via the LDLR (LDL receptor) and SORT1 (sortilin-1), independently of the renin–angiotensin system. Objectives: To investigate the physiological role of (P)RR in lipid metabolism in vivo. Methods and Results: We used N-acetylgalactosamine modified antisense oligonucleotides to specifically inhibit hepatic (P)RR expression in C57BL/6 mice and studied the consequences this has on lipid metabolism. In line with our earlier report, hepatic (P)RR silencing increased plasma LDL-C (LDL cholesterol). Unexpectedly, this also resulted in markedly reduced plasma triglycerides in a SORT1-independent manner in C57BL/6 mice fed a normal- or high-fat diet. In LDLR-deficient mice, hepatic (P)RR inhibition reduced both plasma cholesterol and triglycerides, in a diet-independent manner. Mechanistically, we found that (P)RR inhibition decreased protein abundance of ACC (acetyl-CoA carboxylase) and PDH (pyruvate dehydrogenase). This alteration reprograms hepatic metabolism, leading to reduced lipid synthesis and increased fatty acid oxidation. As a result, hepatic (P)RR inhibition attenuated diet-induced obesity and hepatosteatosis. Conclusions: Collectively, our study suggests that (P)RR plays a key role in energy homeostasis and regulation of plasma lipids by integrating hepatic glucose and lipid metabolism.
Going from A to Z
Authors: Deepak Atri, David Furfaro, Gurpreet Dhaliwal, Kenneth R. Feingold, Reza Manesh
Journal: New England Journal of Medicine (2018)

A 70-year-old man presented to the emergency department with a 3-month history of diarrhea, without blood or mucus. He also noted nausea, nonbloody emesis, and weight loss.
Non-Random Interactions between Founder and Subclonal Mutations Shape the Clinical and Morphological Features of MDS
Authors: Yasunobu Nagata, Hideki Makishima, Cassandra M. Hirsch, Mai Aly, Abhinav Goyal, Hassan Awada, Mohammad Fahad B Asad, Teodora Kuzmanovic, Bartlomiej P. Przychodzen, Hiromichi Suzuki, Tetsuichi Yoshizato, Kenichi Yoshida, Kenichi Chiba, Hiroko Tanaka, Yuichi Shiraishi, Satoru Miyano, Sudipto Mukherjee, Tomas Radivoyevitch, Thomas Laframboise, Aziz Nazha, Mikkael A. Sekeres, Torsten Haferlach, Seishi Ogawa, Jaroslaw P. Maciejewski
Journal: Blood (2017)
Time to Improve Bortezomib and Lenalidomide Lines of Therapy
Authors: Stephanie Guidez, Hélène Demarquette, Denis Caillot, Artur J. Jurczyszyn, Brigitte Pegourie, Marie Lorraine Chretien, Charles Lancesseur, Lionel Karlin, Cristina Joao, Valentine Richez, Laurent Garderet, Souhila Ikhlef, Bruno Royer, Cyrille Hulin, Anne Banos, Eric Voog, Anne-Marie Stoppa, Lofti Benboubker, Niels Abildgaard, Katell Le Du, Philippe Moreau, Thierry Facon, Sonja Zweegman, Margaret Macro, Evangelos Terpos, Xavier Leleu
Journal: Blood (2017)
Pre-Clinical Development of Targeted Therapies for Double Hit (DH) Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: Cory Mavis, Pallawi Torka, Alison Zeccola, Priyank P. Patel, Juan Gu, Matthew J. Barth, Francisco J. Hernandez-Ilizaliturri
Journal: Blood (2017)
Changes in V-ATPase subunits of human urinary exosomes reflect the renal response to acute acid/alkali loading and the defects in distal renal tubular acidosis
Authors: Ganesh Pathare, Nasser A. Dhayat, Nilufar Mohebbi, Carsten A. Wagner, Ion A. Bobulescu, Orson W. Moe, Daniel G. Fuster
Journal: Kidney International (2018)
Important changes in the timing of influenza epidemics in the WHO European Region over the past 20 years: virological surveillance 1996 to 2016
Authors: Saverio Caini, François Schellevis, Clotilde El-Guerche Séblain, John Paget
Journal: Eurosurveillance (2018)

IntroductionThe global epidemiology of many infectious diseases is changing, but little attention has been paid to whether the timing of seasonal influenza epidemics changed in recent years. This study investigated whether the timing of the peak of influenza epidemics has changed in countries of the World Health Organization (WHO) European Region between 1996 and 2016. Methods: Surveillance data were obtained from the WHO FluNet database. For each country and season (July to June of the next year), the peak was defined as the week with the highest 3-week moving average for reported cases. Linear regression models were used to test for temporal trends in the timing of the epidemic peak in each country and to determine whether this differed geographically. Results: More than 600,000 influenza cases were included from 38 countries of the WHO European Region. The timing of the epidemic peak changed according to a longitudinal gradient, occurring progressively later in Western Europe (e.g. by 2.8 days/season in Spain) and progressively earlier in Eastern Europe (e.g. by 3.5 days/season in the Russian Federation). Discussion: These results were confirmed in several sensitivity analyses. Our findings have implications for influenza control and prevention measures in the WHO European Region, for instance for the implementation of influenza vaccination campaigns.
Temporal Trends of De Novo Malignancy Development After Heart Transplantation
Authors: Jong-Chan Youn, Josef Stehlik, Amber R. Wilk, Wida Cherikh, In-Cheol Kim, Gyeong-Hun Park, Lars H. Lund, Howard J. Eisen, Do Young Kim, Sun Ki Lee, Suk-Won Choi, Seongwoo Han, Kyu-Hyung Ryu, Seok-Min Kang, Jon A. Kobashigawa
Journal: Journal of the American College of Cardiology (2018)
Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma
Authors: Huijuan Song, Pingsheng Huang, Jinfeng Niu, Gaona Shi, Chuangnian Zhang, Deling Kong, Weiwei Wang
Journal: Biomaterials (2018)
Exome Array Analyses Identify New Genes Influencing Survival Outcomes after HLA-Matched Unrelated Donor Blood and Marrow Transplantation
Authors: Qianqian Zhu#, Li Yan#, Qian Liu, Qiang Hu, Leah Preus, Alyssa I. Clay, Kenan Onel, Daniel O. Stram, Loreall C. Pooler, Xin Sheng, Christopher A. Haiman, Xiaochun Zhu, Stephen R. Spellman, Marcelo C. Pasquini, Philip L. McCarthy, Song Liu, Theresa Hahn, Lara E. Sucheston-Campbell
Journal: Blood (2016)
Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry
Authors: Inmaculada Medina-Caliz, Miren Garcia-Cortes, Andres Gonzalez-Jimenez, Maria R. Cabello, Mercedes Robles-Diaz, Judith Sanabria-Cabrera, Rocio Sanjuan-Jimenez, Aida Ortega-Alonso, Beatriz García-Muñoz, Inmaculada Moreno, Miguel Jimenez-Perez, M Carmen Fernandez, Pere Ginés, Martin Prieto, Isabel Conde, Hacibe Hallal, German Soriano, Eva Roman, Agustin Castiella, Encarnacion Blanco-Reina, Maria R. Montes, Marta Quiros-Cano, Flores Martin-Reyes, M. Isabel Lucena, Raul J. Andrade, RJ Andrade, MI Lucena, C Stephens, M García-Cortés, M Robles-Díaz, I Medina-Cáliz, J Sanabria, B García-Muñoz, R Alcántara, I Moreno, A Gonzalez-Jimenez, A Ortega-Alonso, R Sanjuán-Jiménez, M Quirós, F Martín-Reyes, A Papineau, M Jiménez-Pérez, R González-Grande, MC Fernández, G Peláez, M Casado, M González-Sánchez, M Romero-Gómez, R Calle-Sanz, R Millán-Domínguez, B Fombuena, R Gallego, L Rojas, A Rojas, J Ampuero, JA del Campo, A Gil Gómez, E Vilar, A Castiella, EM Zapata, L Zubiaurre, JM Navarro, IM Méndez-Sánchez, A Chaves, G Soriano, C Guarner, EM Román, H Hallal, E García-Oltra, JC Titos-Arcos, A Pérez-Martínez, C Sánchez-Cobarro, JM Egea-Caparrós, J Arenas, MI Gomez-Osua, A Gómez-García, FJ Esandi, S Blanco, P Martínez-Odriozola, P Otazua, J Salmerón, A Gila, R Quiles, JM González, S Lorenzo, M Prieto, I Conde, None Amiel, M Berenguer, M García-Eliz, J Primo, JR Molés, A Garayoa, M Carrascosa, E Gómez- Domínguez, E Montané, AL Arellano, AM Barriocanal, Y Sanz, RM Morillas, M Sala, H Masnou, M Farré, M Bruguera, P Gines, S Lens, JC García, A Aldea-Perona, M Hernández-Guerra, M Moreno-San Fiel, C Boada-Fernández del Campo, M Tejedor, R González-Ferrer, C Fernández, M Fernández-Gil, JL Montero, M de la Mata, J Fuentes-Olmo, EM Fernández-Bonilla, J González-Gallego, F Jorquera, JM Moreno, P Martínez-Rodenas, M Garrido, P Rendón, M Vergara, J Sánchez Delgado, J García Samaniego, A Madejón, JL Cabriada, J Crespo, A Giráldez Gallego, M Cuaresma, R Ruíz
Journal: Clinical Gastroenterology and Hepatology (2018)
Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria
Authors: Antonio M. Risitano, Serena Marotta
Journal: American Journal of Hematology (2018)

Abstract Therapeutic complement inhibition by eculizumab has revolutionized the treatment of paroxysmal nocturnal hemoglobinuria (PNH) with a major impact on its natural history. Nevertheless, emerging unmet clinical needs may benefit from the development of novel complement inhibitors. Novel strategies of complement inhibition exploit different agents targeting C5, as well as compound intercepting the complement cascade at the level of its key component C3, or even upstream at the level of components involved in complement alternative pathway initiation. Many of these agents are already in their clinical development; preliminary data together with a deep understanding of PNH biology may help to anticipate their possible clinical effect. Novel anti‐C5 agents include monoclonal antibodies (even long‐lasting) as well as other small molecules bioavailable by subcutaneous administration; an anti‐C5 small interfering RNA has been developed too. All these anti‐C5 agents seem to recapitulate safety and efficacy of current eculizumab treatment; their main improvement pertains to better patient's convenience due to longer dosing interval and/or possible subcutaneous self‐administration. The possibility of achieving a deeper C5 inhibition has been shown as well, but its actual clinical meaning remains to be elucidated. Upstream complement inhibitors include the anti‐C3 small peptide compstatin (and its derivatives), and small inhibitors of complement factor D or complement factor B. This class of compounds anticipates a possible efficacy in prevention of C3‐mediated extravascular hemolysis, in addition to inhibition of intravascular hemolysis, eventually leading to improved hematological responses. The availability of all these compounds will result soon in a substantial improvement of PNH management.
The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis
Authors: Yan-Xiao Ji, Zan Huang, Xia Yang, Xiaozhan Wang, Ling-Ping Zhao, Pi-Xiao Wang, Xiao-Jing Zhang, Michele Alves-Bezerra, Lin Cai, Peng Zhang, Yue-Xin Lu, Lan Bai, Mao-Mao Gao, Huan Zhao, Song Tian, Yong Wang, Zhi-Xiang Huang, Xue-Yong Zhu, Yan Zhang, Jun Gong, Zhi-Gang She, Feng Li, David E Cohen, Hongliang Li
Journal: Nature Medicine (2018)
Abstract 14659: The Association Between Arterial Carbon Dioxide Tension and Outcomes After Cardiac Arrest: A Systematic Review and Meta-analysis
Authors: Nicole F Mckenzie, Teresa A Williams, Hideo Tohira, Kwok M Ho, Judith Finn
Journal: Circulation (2016)

Introduction: Arterial carbon dioxide (PaCO2) elimination is impaired during cardiac arrest (CA) due to inadequate perfusion of the lungs. Both high and low PaCO2 after return of spontaneous circul...